Navigation Links
Shire Presents Positive New Data at the 60th Annual American Society of Human Genetics (ASHG) for Patients with Type 1 Gaucher Disease
Date:11/4/2010

rval of –0.60 g/dL in both populations, greater than the pre-defined non-inferiority margin of –1.0 g/dL. These results indicate that the primary endpoint was met. Both the VPRIV and imiglucerase groups showed substantial improvements in the secondary endpoints, including platelet counts, spleen volume, liver volume, and plasma biomarkers with no statistically significant difference demonstrated between the treatment groups. The majority of adverse events were mild or moderate in severity, including one serious adverse event (SAE) seen with VPRIV which was an allergic skin reaction that resolved without sequalae.

Shire also reported important findings that suggested substantial antigenic differences when antibody response to treatment with VPRIV and imiglucerase were compared. No patient treated with VPRIV developed anti-drug antibodies while 4 patients in the imiglucerase group developed antibodies to imiglucerase. Of these four imiglucerase treated patients, 1 patient had antibodies that inhibited enzyme activity in vitro and enzyme uptake in a cell-based assay. 3 patients had antibodies that did not inhibit enzyme activity or uptake.

Data from the Phase III clinical trial extension were also presented at ASHG. In the six month extension study patients from study 034 with type 1 Gaucher disease previously treated with imiglucerase, successfully transitioned to VPRIV and maintained hematological parameters at therapeutic levels through 18 months of continuous treatment. VPRIV was generally well tolerated, and appeared to show a favourable immunogenicity profile.

"For physicians, drug safety is a major consideration; the reported lack of antibodies to infused velaglucerase alfa in these studies, both in naive and switch patients, is re-assuring to patients and their physicians alike," said Gregory M. Pastores MD, Associate Professor of Neurology and Pediatrics at the NYU School of Medicine in New York.

Shire's VPRIV clinical t
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
2. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
3. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
4. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
5. Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
6. Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
7. Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
8. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
9. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
10. Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
11. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... LONDON , April 21, 2015 ... for Enterprise, having achieved dazzling export-led growth in ... London™ today celebrates its part in winning the ... International Trade, awarded to Oxford PharmaGenesis. As part ... London helps its clients bring new medicines to ...
(Date:4/21/2015)... -- This report analyzes the worldwide markets for Apheresis ... for Therapeutic Apheresis, and Equipment for Donor Apheresis. Global ... Plateletpheresis, and Others. The report provides separate comprehensive analytics ... Japan , Europe , ... Annual estimates and forecasts are provided for the period ...
(Date:4/21/2015)... -- Cardiologists at Henry Ford Hospital have implanted a device ... irregular heartbeat. With only handful of hospitals in ... able to add another option to its arsenal of tools ... ability to pump. "This is a first ... implant at a non-clinical trial site," says cardiologist Claudio ...
Breaking Medicine Technology:Queen's Award Crowns Achievements of Fast-growing London Consultancy 2Queen's Award Crowns Achievements of Fast-growing London Consultancy 3Queen's Award Crowns Achievements of Fast-growing London Consultancy 4Queen's Award Crowns Achievements of Fast-growing London Consultancy 5World Apheresis Equipment Industry 2World Apheresis Equipment Industry 3World Apheresis Equipment Industry 4World Apheresis Equipment Industry 5World Apheresis Equipment Industry 6World Apheresis Equipment Industry 7World Apheresis Equipment Industry 8World Apheresis Equipment Industry 9World Apheresis Equipment Industry 10World Apheresis Equipment Industry 11World Apheresis Equipment Industry 12World Apheresis Equipment Industry 13World Apheresis Equipment Industry 14World Apheresis Equipment Industry 15World Apheresis Equipment Industry 16World Apheresis Equipment Industry 17World Apheresis Equipment Industry 18World Apheresis Equipment Industry 19World Apheresis Equipment Industry 20World Apheresis Equipment Industry 21Stroke Risk Caused by Abnormal Heart Rhythm Reduced Without Blood Thinners 2Stroke Risk Caused by Abnormal Heart Rhythm Reduced Without Blood Thinners 3
(Date:4/21/2015)... (PRWEB) April 21, 2015 Top medical ... in India for their ongoing commitment to providing superior ... strives to provide patients with the best possible experience ... skin, hair and body. , Executives at Ojas Aesthetic ... the philosophy of — nothing about you, without you ...
(Date:4/21/2015)... Jersey City, NJ (PRWEB) April 21, 2015 ... enterprise collaboration across platforms and devices, today announced a ... the integration of the new Microsoft Office 365 Management ... that allows customers to fully audit and take action ... 365 environments. , “The new Office 365 Management Activity ...
(Date:4/21/2015)... WA (PRWEB) April 21, 2015 ... Practice Edition 2 for otolaryngologists, bringing the most ... the healthcare community. Otolaryngologists can now experience ... by a trusted source in the industry, Lyft, ... integration with leading EHRs. , “Lyft is very ...
(Date:4/21/2015)... CA (PRWEB) April 21, 2015 Edward ... and Arthur “A.G.” Kawamura, former Secretary of the California ... featured speakers for the 2nd Annual GrowRIVERSIDE Conference: The ... , The inclusion of these nationally known experts ... experts, city planners, farmers and others slated to speak ...
(Date:4/21/2015)... Further strengthening ties between the two institutions, ... goods and services to the University of South Florida ... BRIDGE Healthcare Clinic. , The BRIDGE clinic – a ... year – provides primary medical care to more than ... inside the USF Health Morsani Center for Advanced Healthcare. ...
Breaking Medicine News(10 mins):Health News:VisitandCare.com Cosmetic Surgery Provider in India Earns Recognition for Patient Satisfaction 2Health News:VisitandCare.com Cosmetic Surgery Provider in India Earns Recognition for Patient Satisfaction 3Health News:AvePoint Integrates Microsoft Office 365 Management Activity API into DocAve Policy Enforcer for Proactive SharePoint Monitoring 2Health News:AvePoint Integrates Microsoft Office 365 Management Activity API into DocAve Policy Enforcer for Proactive SharePoint Monitoring 3Health News:Lyft Expands Its Offerings to Include Dragon® Medical Practice Edition 2 for Otolaryngologists. 2Health News:USDA Under Secretary, former CA Agriculture Director to Address 2nd Annual “GrowRIVERSIDE” Conference in June 2Health News:USDA Under Secretary, former CA Agriculture Director to Address 2nd Annual “GrowRIVERSIDE” Conference in June 3Health News:USF Health and Florida Hospital Tampa Partner to Expand BRIDGE Clinic 2Health News:USF Health and Florida Hospital Tampa Partner to Expand BRIDGE Clinic 3
... the insulin gene to diabetes patients using nanoparticles, was presented ... Society of Gene Therapy (ASGT) in Seattle. ,Type ... the insulin producing pancreatic -cells. As a result of the ... damage to fine blood vessels and nerve endings leading to ...
... with culture-positive tuberculosis (TB), relapse rates were found ... compared to HIV-uninfected patients following a rifamycin-based regimen. ... patients who received intermittent or standard 6-month therapy ... treatment. ,The results appear in the ...
... But one should pop the pill just before sex. The ... good news for those suffering from erectile dysfunction (ED) - ... than the pills. ,Human and animal trials suggest ... treatments available. A University of Pittsburgh team, led by Dr ...
... CHICAGO:- Scientific advances have enabled better diagnosis and treatment ... presented at the world's premier conference on cancer. "We've ... unique to women," Julie Gralow, assistant professor of oncology ... ,"The studies discussed today bring us even closer ...
... CHICAGO, Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, ... extended overall survival in patients with hepatocellular ... taking placebo by 44%. Results were presented at ... of Clinical Oncology (ASCO). ,The international, ...
... new climate plan of the US should complement rather than ... Climate Change (UNFCCC), China's top economic planner Ma Kai ... common but differentiated responsibilities in the UNFCCC and some details ... other countries, Ma said at a press conference. ...
Cached Medicine News:Health News:Novel Delivery Method of Insulin Gene to Combat Juvenile Diabetes Developed 2Health News:Treatment Outcomes of Patients With HIV and Tuberculosis 2Health News:Gene Therapy a Better Alternative to Viagra Please 2Health News:Advanced Scientific Brings Help for Breast Cancer Survivors 2Health News:Nexavar Significantly Extends Survival of Liver Cancer Patients 2
... chairs with concave seats and standard-sized ... options like seats, backrests, armrests, and ... are recommended for the following environments: ... control, health care and office. • ...
... Basic ergonomic chairs with concave seats ... • Select options like seats, backrests, ... BTP/1Q-PAL chairs are recommended for the ... room, static control, health care and ...
... concave seats and standard-sized backrests with ... seats, backrests, armrests, and casters and ... for the following environments: industry, education, ... care and office. • With polished ...
... Basic ergonomic chairs with concave ... support • Select options like seats, ... • BTN/1Q-CAB chairs are recommended for ... clean room, static control, health care ...
Medicine Products: